Staphylococcus aureus toxoid vaccine - Integrated BioTherapeuticsAlternative Names: AT62; Glycoprotein conjugated S. aureus toxoid vaccine
Latest Information Update: 10 Aug 2016
At a glance
- Originator Integrated BioTherapeutics
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Staphylococcal infections
Most Recent Events
- 04 Apr 2016 Phase-I clinical trials in Staphylococcal infections in USA (Parenteral)